Tectonic Therapeutic Inc
TECX20.855USD
+0.125+0.60%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
389.39MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Tectonic Therapeutic Inc Unternehmen
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).
Unternehmensinformationen
BörsenkürzelTECX
Name des UnternehmensTectonic Therapeutic Inc
IPO-datumJun 21, 2018
CEODr. Alise S. Reicin, M.D.
Anzahl der mitarbeiter51
WertpapierartOrdinary Share
GeschäftsjahresendeJun 21
Addresse490 Arsenal Way
StadtWATERTOWN
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02472
Telefon13396663320
Websitehttps://tectonictx.com/
BörsenkürzelTECX
IPO-datumJun 21, 2018
CEODr. Alise S. Reicin, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Jul 22
Aktualisiert: Tue, Jul 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
Aktionäre
Aktionäre
Anteil
Springer Timothy A
23.68%
Fidelity Management & Research Company LLC
14.99%
Deep Track Capital LP
7.51%
TAS Partners, L.L.C.
7.41%
EcoR1 Capital, LLC
5.01%
Other
41.40%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
27.37%
Hedge Fund
24.98%
Investment Advisor
22.57%
Corporation
10.93%
Investment Advisor/Hedge Fund
7.56%
Venture Capital
2.74%
Research Firm
2.25%
Pension Fund
0.12%
Family Office
0.05%
Other
1.43%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
178
18.44M
98.77%
+1.52M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
Prosight Capital
398.88K
2.14%
+398.88K
--
Mar 31, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.8%
iShares Micro-Cap ETF
Anteil0.05%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
iShares Biotechnology ETF
Anteil0.02%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Datum
Art
Verhältnis
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
Jun 18, 2024
Merger
12<1
